6,13,21,28-Tetraoxa-4,15,19,30-tetrazaheptacyclo[16.12.0.03,16.05,14.07,12.020,29.022,27]triaconta-1(18),2,4,7,9,11,14,16,19,22,24,26,29-tridecaene

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 6,13,21,28-Tetraoxa-4,15,19,30-tetrazaheptacyclo[16.12.0.03,16.05,14.07,12.020,29.022,27]triaconta-1(18),2,4,7,9,11,14,16,19,22,24,26,29-tridecaene
• 化学式: C₂₂H₁₀N₄O₄
• 分子量: 394.3
• InChiKey: OCURXTQKMLEUHZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  30
• 可旋转键数：
  0
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  88.5
• 氢给体数：
  0
• 氢受体数：
  8

文献信息

• LANTHIONINE SYNTHETASE COMPONENT C-LIKE PROTEINS AS MOLECULAR TARGETS FOR PREVENTING AND TREATING DISEASES AND DISORDERS
  申请人：Virginia Tech Intellectual Properties, Inc.

  公开号：EP2567225A2

  公开（公告）日：2013-03-13
• US9101573B2
  申请人：——

  公开号：US9101573B2

  公开（公告）日：2015-08-11
• [EN] LANTHIONINE SYNTHETASE COMPONENT C-LIKE PROTEINS AS MOLECULAR TARGETS FOR PREVENTING AND TREATING DISEASES AND DISORDERS<br/>[FR] PROTÉINES ANALOGUES AU COMPOSANT C DE LANTHIONINE SYNTHÉTASE COMME CIBLES MOLÉCULAIRES POUR PRÉVENTION ET TRAITEMENT DE MALADIES ET DE TROUBLES
  申请人：VIRGINIA TECH INTELL PROP

  公开号：WO2011140215A2

  公开（公告）日：2011-11-10

  The present invention relates to the field of medical treatments for diseases and disorders. More specifically, the present invention relates to the use of the lanthionine synthetase component C-like (LANCL) proteins as therapeutic targets for novel classes of anti-inflammatory, immune regulatory and antidiabetic drugs. This includes but it is not limited to abscisic acid (ABA), ABA analogs, benzimidazophenyls, repurposed drugs or drug combinations, including thiazolidinediones (TZDs); naturally occurring compounds such as conjugated diene fatty acids, conjugated triene fatty acids, isoprenoids, and natural and synthetic agonists of peroxisome proliferator- activated receptors that activate this receptor through an alternative mechanism of action involving LANCL2 or other membrane proteins to treat or prevent the common inflammatory pathogenesis underlying type 2 diabetes, atherosclerosis, cancer, some inflammatory infectious diseases such as influenza and autoimmune diseases including but not limited to inflammatory bowel disease (Crohn's disease and Ulcerative colitis), rheumatoid arthritis, multiple sclerosis and type 1 diabetes and other chronic inflammatory conditions.